Treatment with navenibart, or STAR-0215, safely reduced the rate of monthly swelling attacks by 90% to 95% in…
Articles by Patricia Inácio, PhD
Stroke patients treated with alteplase, a medication used to dissolve blood clots, are at an increased risk of developing…
Orladeyo (berotralstat), an oral therapy designed to reduce or prevent hereditary angioedema (HAE) attacks, is now available in Ireland.
An 80-year-old man in Texas developed angioedema thought to be triggered by the antipsychotic therapy risperidone, according to a…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to navenibart — the …
People with hereditary angioedema (HAE) in Japan with access to on-demand therapies alone can have a high rate of…
Race and geographic disparities are common in clinical trials of hereditary angioedema (HAE), with non-white patients and countries outside…
People with hereditary angioedema (HAE) typically experience a markedly delayed diagnosis — from three to 26 years following the…
Children in Egypt with hereditary angioedema (HAE) wait an average of three years to be diagnosed, according to a small…
Otsuka Pharmaceutical has obtained exclusive rights to commercialize donidalorsen for hereditary angioedema (HAE) in the Asia-Pacific region. The…